<DOC>
	<DOCNO>NCT01446211</DOCNO>
	<brief_summary>The aim study ass efficacy ( superiority test ) gusperimus compare conventional treatment patient relapse Wegener Granulomatosis without ongoing steroid , and/or immunosuppressive therapy . Further , evaluate safety quality life gusperimus treatment compare standard treatment patient relapse Wegener Granulomatosis receive glucocorticoid .</brief_summary>
	<brief_title>Clinical Study Comparing New Immunosuppressive Drug Gusperimus With Conventional Treatment Wegener 's Granulomatosis</brief_title>
	<detailed_description>Wegener Granulomatosis without treatment life-threatening . The standard treatment corticosteroid cyclophosphamide usually effective control active disease . However , disease relapse frequent require increased exposure toxic drug . In patient initiation continuation standard drug contraindicate due intolerable side effect . No well-established therapy available relapsing patient . They may suffer severe organ damage due progressive disease , may die . The propose indication gusperimus treatment relapse Wegener Granulomatosis . The aim therapy gusperimus induce maintain remission thereby avoid cyclophosphamide reduce corticosteroid exposure .</detailed_description>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Gusperimus</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>1 . Documented diagnosis Wegener 's Granulomatosis ( WG ) accord American College Rheumatology classification criterion . 2 . Diagnosis WG least 6 month entry initial induction therapy combination Glucocorticoids immunosuppressive ( Cyclophosphamide Methotrexate ) rituximab . 3 . Relapse WG without ongoing Glucocorticoids , and/or immunosuppressive therapy Azathioprine/Mycophenolate Mofetil/Methotrexate Leflunomide . The minimum disease activity define presence one new/worse major three new/worse minor BVAS ( version 3 ) item . 4 . Patients 18 75 year . 5 . Medically acceptable reliable contraception method study course . ( Women become pregnant least 6 month Cyclophosphamide treatment ) . 6 . Written inform consent study participation give patient . 7 . Patients able prepared selfadminister study medication relative/third person able . 8 . Ability read , understand record information require protocol 1 . Other multisystem autoimmune disorder , include systemic lupus erythematosus antiGlomerular Basement Membrane disease . 2 . Systemic vasculitis due viral infection . 3 . Cyclophosphamide therapy intolerance , hypersensitivity contraindication Cyclophosphamide ( active substance excipients ) patient severe relapse WG . 4 . Hypersensitivity contraindication Spanidin ( active substance excipients ) Methotrexate ( active substance excipients ) Azathioprine ( active substance excipients ) methylprednisolone , prednisolone corticosteroid ( active substance excipients ) . 5 . Underlying medical condition , opinion Investigator place patient unacceptable risk level participate study . 6 . Previous randomisation study . 7 . Cyclophosphamide , intravenous immunoglobulin , anticytokine biologic therapy , plasma exchange Abatacept three month prior entry trial . Rituximab , Alemtuzumab stem cell transplantation permit six month prior entry trial . 8 . Previous treatment gusperimus . 9 . Participation another clinical trial investigational drug within last 3 month screen present trial period . 10 . Pregnant breastfeeding female . 11 . Active bacterial/viral infection ( Human Immunodeficiency Virus , Hepatitis B , Hepatitis C , Tuberculosis ) . 12 . Patients Glomerular Filtration Rate ( eGFR ) &lt; 15 mL/min/1.73m2 . 13 . Alanine transaminase ( ALT ) , Aspartate aminotransferase ( AST ) , bilirubin , Alkaline phosphatase ( ALP ) level 2 x upper normal limit . 14 . Inadequate bonemarrow function : White Blood Cells ( WBC ) &lt; 4000/mm3 , haemoglobin &lt; 8 g/dL , neutrophils &lt; 2500/mm3 , platelet &lt; 100 000/mm3 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>gusperimus</keyword>
	<keyword>Wegeners granulomatosis</keyword>
	<keyword>relapse</keyword>
</DOC>